AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

(2011) James L. Mohler et al.   CANCER RESEARCH

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway

(2011) G. Attard et al.   CLINICAL CANCER RESEARCH

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors

(2010) C. M. Robbins et al.   GENOME RESEARCH

Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome

(2010) A. R. Quinlan et al.   GENOME RESEARCH

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

(2010) P. A. Watson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy

(2009) M. P. Steinkamp et al.   CANCER RESEARCH

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

(2009) M. A. Leversha et al.   CLINICAL CANCER RESEARCH

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

(2009) Yu Chen et al.   LANCET ONCOLOGY

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

(2009) Wennuan Liu et al.   NATURE MEDICINE

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor

(2008) A. Dagvadorj et al.   CLINICAL CANCER RESEARCH